Anavex Life Sciences Corp
$ 4.36
4.81%
24 Feb - close price
- Market Cap 385,514,000 USD
- Current Price $ 4.36
- High / Low $ 4.42 / 4.15
- Stock P/E N/A
- Book Value 1.37
- EPS -0.46
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.22 %
- ROE -0.34 %
- 52 Week High 13.99
- 52 Week Low 2.86
About
Anavex Life Sciences Corp. The company is headquartered in New York, New York.
Analyst Target Price
$22.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-05 | 2025-11-25 | 2025-08-12 | 2025-05-07 | 2025-02-05 | 2024-11-25 | 2024-08-06 | 2024-05-09 | 2024-02-07 | 2023-11-27 | 2023-08-08 | 2023-05-09 |
| Reported EPS | -0.06 | -0.11 | -0.16 | -0.1316 | -0.14 | -0.14 | -0.14 | -0.13 | -0.11 | -0.12 | -0.14 | -0.17 |
| Estimated EPS | -0.1243 | -0.1426 | -0.1457 | -0.15 | -0.17 | -0.17 | -0.16 | -0.11 | -0.14 | -0.15 | -0.17 | -0.19 |
| Surprise | 0.0643 | 0.0326 | -0.0143 | 0.0184 | 0.03 | 0.03 | 0.02 | -0.02 | 0.03 | 0.03 | 0.03 | 0.02 |
| Surprise Percentage | 51.7297% | 22.8612% | -9.8147% | 12.2667% | 17.6471% | 17.6471% | 12.5% | -18.1818% | 21.4286% | 20% | 17.6471% | 10.5263% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.1255 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AVXL
2026-02-14 23:57:25
Anavex Life Sciences (NASDAQ:AVXL) was upgraded by Wall Street Zen from "sell" to "hold," resulting in a consensus "Hold" rating and a $22.00 target price. Despite beating quarterly EPS estimates, the company faces a negative FY2026 EPS outlook, with its stock trading below key moving averages. Institutional ownership has increased, with State Street Corp significantly boosting its stake, now holding approximately 31.55% of the company's shares.
2026-02-10 13:27:45
Anavex Life Sciences Corp. discussed its Q1 2026 financial results and advancements in its clinical pipeline, particularly for oral blarcamesine in early Alzheimer's disease. The company addressed the EMA's negative opinion on blarcamesine's marketing authorization application, stating it is undergoing reexamination, and detailed plans for an upcoming FDA submission. Anavex also highlighted its participation in the European Access AD initiative, which will include a dedicated clinical trial for blarcamesine.
2026-02-09 21:58:36
Anavex Life Sciences Corp. released its Form 10-Q report for the third quarter, reporting significantly improved financial performance with reduced operating and net losses. The biopharmaceutical company highlighted operational advancements, including ongoing clinical trials for central nervous system diseases like Alzheimer's and Parkinson's, regulatory submissions, and a precision medicine approach. Anavex plans to continue advancing its clinical programs and seek strategic partnerships, leveraging its Orphan Drug and Fast Track designations for ANAVEX®2-73.
2026-02-09 13:58:36
Anavex Life Sciences Corp. (AVXL) reported a fiscal first-quarter loss of $5.7 million, or 6 cents per share. The company's shares closed at $4.10, a significant decrease from $8.51 a year ago. This financial update was generated by Automated Insights using Zacks Investment Research data.
2026-02-09 12:58:36
Anavex Life Sciences Corp. reported a significantly narrower net loss of $5.7 million in fiscal Q1 2026, down from $12.1 million in the prior year, primarily due to reduced operating expenses. The company also strengthened its cash reserves, ending the quarter with $131.7 million, and continues to focus on advancing its lead candidate, blarcamesine, for Alzheimer's and other CNS disorders. Anavex anticipates a cash runway of over three years at its current utilization rate.
2026-02-09 12:58:36
Anavex Life Sciences has reported a net loss of $5.7 million for its fiscal first quarter, translating to a loss of $0.06 per share. The company's shares closed at $4.10, marking a substantial drop from $8.51 recorded in the same period last year. This financial update details the company's performance for the quarter.
